Highlights
- 1The Journal of investigative dermatology · 2021
- 2Pigment cell & melanoma research · 2024
- 3Cell reports · 2022
Publications
Funding
Active
5 grants- PIR01AR077664-06Mechanisms of cAMP-dependent regulation of melanosome pHNational Inst of Arthritis & Musculoskeletal & Skin Diseases · 2021–2031· 2 renewals
- PISRA 233593-03Evaluation of Vitamin C in melanocytesL'Oreal USA · 2023–2028Contract
- PIVCF 253766-01Examination of sAC inhibitors as a method to treat oculocutaneous albinismVision of Children Foundation · 2026–2027
- MPIUL1TR002384-06Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1CTSC Cost Share · 2022–2027
- PINOAH 262096-01Development of in-tissue assessment of melanin synthesis to test OCA therapeuticsNational organization for albinism and hypopigmentation · 2026–2027
Completed grants (11)
- PIR13AR084871-01The PanAmerican Society for Pigment Cell Research (PASPCR) 25th annual conference entitled "Where pigment cell research never sleeps"National Inst of Arthritis & Musculoskeletal & Skin Diseases · 2024–2025
- PINOAH 231391-02Development of soluble adenylyl cyclase inhibitors to improve ocular pigmentation.National organization for albinism and hypopigmentation · 2023–2025
- KPDF 227417-01Metabolic profiling of melanosome and global cellular metabolism in melanomaDermatology Foundation · 2023–2024
- PIHTI 202399-02Examination of RAMBA Ability to Block Acne Pathogenic Gene Expression in Human KeratinocytesHoth Therapeutics, Inc. · 2019–2021BioPharma Alliance
- PI51756601Mechanism of action of Crisaborole in human keratinocytesPfizer Inc. · 2019–2021Contract
- MPIR21CA224391-02Uncovering the role of m6A in the melanocyte response to ultraviolet lightNational Cancer Institute · 2018–2020
- Co-IHHSN261201700005CValidation of SHADE a Mobile Technology for Monitoring of Ultraviolet ExposureNational Cancer Institute · 2017–2019 · via YouV Labs
- PIASA 181188-01Novel cAMP Signaling Pathway Regulates Melanosome pH and PigmentationAmerican Skin Association, Inc. · 2018–2019
- PIMRF 184310-01Vitamin C as a novel therapeutic for melanomaMelanoma Research Foundation · 2018–2019
- PICelgene SRAEstablish the Relevant PDE4- and PDE7-sensitive cAMP Microdomains in Psoriasis Pathogenesis.Celgene Corporation · 2017–2018Contract
- PIK08CA160657-05cAMP signaling in melanoma pathogenesis: Evidence for multiple microdomains playiNCI · 2011–2016 · via NIH RePORTER
Clinical research
Active
2 studies- PIVitamin D deficiency and its association with allergic contact dermatitis: a retrospective cohort analysisWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIContact Dermatitis Patch Test Database Protocol; Weill Cornell Dermatology Contact Dermatitis and Patch Testing Unit in collaboration with the North American Contact Dermatitis GroupWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (1)
- PIType IV Hypersensitivity Patch Testing in a Cohort of 55 Patients with a History of Cancer: A Retrospective Chart Review StudyWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
Available technologies
- Modulation of soluble Adenylyl Cyclase (sAC) as a Method of Altering Melanocyte Pigmentation7464Application filedPoC DataPMID 30401788
- 9143
News mentions
- Discovery Could Lead to Drug Therapy for Hypopigmentation ConditionsJuly 14, 2026
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators.
- Novel Technique Reveals Surprising New Way to Suppress Tumor CellsSeptember 27, 2022
By analyzing key enzymes in a new way, an international team led by researchers at Weill Cornell Medicine has discovered how a well-known signaling molecule can either stimulate or suppress tumor growth depending on where it’s produced. The work, published Sept. 27 in Cell Reports, reveals a new aspect of tumor cell biology, and points to a promising strategy for treating many types of cancer. Cells use the small molecule cyclic AMP (cAMP) to trigger different effects largely depending on the proteins it activates. For example, past studies have shown that cAMP can either activate or suppress tumor growth under different circumstances. “Most people have studied cAMP by studying the effector proteins that [mediate its activity], or they've looked at the [enzymes that] inactivate it,” said co-senior author Dr. Jonathan H. Zippin, vice chair of research and an associate professor of dermatology and pharmacology at Weill Cornell Medicine, director of dermatology precision medicine at the Englander Institute for Precision Medicine, and a dermatologist at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Taha Merghoub, deputy director of the Sandra and Edward Meyer Cancer Center, the Margaret and Herman Sokol Professor of Oncology Research and a professor of pharmacology, as well as Dr. Elena Piskounova, an assistant professor of cell biology in dermatology, are also co-senior authors on the study. Instead of turning cAMP signaling on or off across the entire cell, as previous studies had done, Dr. Marek Drozdz, a postdoctoral associate in Dr. Zippin’s lab, wanted to activate cAMP in specific subcellular compartments. Two enzymes can produce cAMP in a cell: one bound to the plasma membrane and one that’s soluble. “We focused on the soluble one, because this source of cAMP could be targeted to different compartments within the cell, and then evoke a little pocket of cAMP signaling in each compartment,” said Dr. Drozdz, who is the lead author on the paper. To do…
- Prestigious Awards and Prizes Presented to Faculty and StudentsJuly 8, 2019
Weill Cornell Medicine faculty members honored with annual awards at Convocation and Commencement for their exemplary achievements.
Mentoring
- JBJakyung BangMD mentee · Class of 2022
- SGSamuel GrondinPharmacology (PhD)
- SSStephanie SutterMD mentee · Class of 2018
- RORachel OrleansMD mentee · Class of 2019
- TWTyler WillsMD-PhD WGS Pharmacology (PhD)
External relationships
Other Interest
Amorepacific Corporation · Hoth Therapeutics, Inc. · Mitsubishi Tanabe Pharma Development America, Inc.